ClinicalTrials.gg
CompletedNCT00616798Updated Jun 24, 2014

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

A Phase 2 interventional study of RO4917838 and RO4917838 in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 73 sites in 10 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
7th of 16
323 · median 294
Started
2008
the only one that year
Phase 2
5 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2008, is one of 5 in phase 2, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent negative or d isorganized thought symptoms. After a 4 week run in period on their current anti psychotic treatment, patients will be randomized to receive placebo 10mg, 30mg, or 60mg of RO4917838 once daily, p.o., as add-on therapy. The anticipated time o n study treatment is \<3 months, and the target sample size is 100-500 individual s.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-60 years of age;
  • diagnosis of schizophrenia (based on screening tests);
  • outpatients, with no hospitalization for worsening of schizophrenia within 3 months;
  • medically and psychiatrically stable over prior 1 month and psychiatrically stable without symptom exacerbation within prior 3 months;
  • currently taking no more than 2 antipsychotic drugs.

Exclusion criteria

Exclusion Criteria:

  • began a new non-medication treatment for schizophrenia or other psychiatric condition within last 3 months;
  • on >1 antidepressant, or a change in dose of antidepressant within 3 months;
  • alcohol or substance abuse or dependence within 3 months;
  • has previously received RO4917838.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    3

    Drug: RO4917838 · Drug: Standard antipsychotic therapy

  • Placebo comparator
    4

    Drug: Placebo · Drug: Standard antipsychotic therapy

  • Experimental
    1

    Drug: RO4917838 · Drug: Standard antipsychotic therapy

  • Experimental
    2

    Drug: RO4917838 · Drug: Standard antipsychotic therapy

Interventions

  • 10mg po daily

  • 30mg po daily

  • 60mg po daily

  • DrugPlacebo

    po daily

  • DrugStandard antipsychotic therapy

    As prescribed

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in PANSS (Positive and Negative Syndrome Scale) negative factor score.

    Time frame: Week 8

Secondary outcomes

  1. Change from baseline in total PANSS score, CGI, PSP, SGLS; cognition status changes.

    Time frame: Throughout study

  2. AEs, laboratory parameters, C-SSRS

    Time frame: Throughout study

07

Study locations

73 sites
  • Granada Hills, California 91344, United States
  • Los Angeles, California 90033, United States
  • Oceanside, California 92056, United States
  • Torrance, California 90502, United States
  • Atlanta, Georgia 30308, United States
  • Hoffman Estates, Illinois 60169, United States
  • Brooklyn, New York 11203, United States
  • Cincinnati, Ohio 45267, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Austin, Texas 78754, United States
  • Austin, Texas 78756, United States
  • De Soto, Texas 75115, United States
  • Irving, Texas 75062, United States
  • Wien, 1010, Austria
  • Wien, 1090, Austria
  • Curitiba, 80520-000, Brazil
  • Pelotas, 96030-002, Brazil
  • Rio de Janeiro, 21020-130, Brazil
  • Salvador, 40301-500, Brazil
  • Sao Paulo, 04044-000, Brazil
  • Sao Paulo, 05403-010, Brazil
  • Marseille, 13009, France
  • Orvault, 44700, France
  • Toulon, 83056, France
  • Achim, 28832, Germany
  • Bochum, 44805, Germany
  • Freiburg, 79104, Germany
  • Hamburg, 20246, Germany
  • Nürnberg, 90402, Germany
  • Westerstede, 26655, Germany
  • Balassagyarmat, 2660, Hungary
  • Budapest, 1083, Hungary
  • Budapest, 1097, Hungary
  • Budapest, 1125, Hungary
  • Budapest, 1135, Hungary
  • GYR, 9024, Hungary
  • Gyula, 5700, Hungary
  • Nyíregyháza, 4400, Hungary
  • Aichi, 470-1192, Japan
  • Chiba, 272-8516, Japan
  • Fukuoka, 807-8555, Japan
  • Fukuoka, 812-8582, Japan
  • Gunma, 373-0054, Japan
  • Kanagawa, 232-0024, Japan
  • Kanagawa, 236-0004, Japan
  • Nagasaki, 852-8501, Japan
  • Saga, 842-0192, Japan
  • Sapporo, 060-8638, Japan
  • Tokushima, 770-8503, Japan
  • Tokyo, 162-8666, Japan
  • Tokyo, 187-8551, Japan
  • Mexico City, 06100, Mexico
  • Mexico City, 11560, Mexico
  • Mexico City, 1400, Mexico
  • Mexico City, 14370, Mexico
  • Monterrey, 64710, Mexico
  • Bydgoszcz, 85-096, Poland
  • Kielce, 25-317, Poland
  • Skorzewo, 60-165, Poland
  • Torun, 87-100, Poland
  • Tuszyn, 95-080, Poland
  • Zuromin, 09-300, Poland
  • Kazan, 420012, Russian Federation
  • Lipetsk, 399313, Russian Federation
  • Moscow, 115522, Russian Federation
  • Moscow, 117152, Russian Federation
  • Moscow, 123367, Russian Federation
  • Nizhny Novgorod, 603155, Russian Federation
  • St Petersbourg, 190005, Russian Federation
  • St Petersburg, 192019, Russian Federation
  • St Petersburg, 193019, Russian Federation
  • St. Petersburg, 193167, Russian Federation
08

References and documents

Publications

  • Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163. PubMed 24696094 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2008
First posted
Feb 15, 2008
Start
Mar 2008
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results delay requested
Aug 20, 2013
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00616798
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 15, 2008
Start date
Mar 2008
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Jun 24, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion